Evaluation of a rapid one-step PSA test for primary prostate cancer screening

BMC Urol. 2021 Sep 27;21(1):135. doi: 10.1186/s12894-021-00903-7.

Abstract

Background: To enhance the convenience and reduce the cost of prostate cancer (PC) screening, a one-step prostate-specific antigen (PSA) test was evaluated in a large population. The PSA SPOT test kit enables rapid detection of human PSA in serum or plasma at or above a cutoff level of 4 ng/mL to aid in the diagnosis of PC.

Methods: PC screening using the PSA SPOT test was offered to male participants in educational public lectures that we conducted in various cities. Test results were reported to participants at the end of the lectures. Blood samples from 1429 men were evaluated. Two independent observers interpreted the tests at 15 and 30 min. The remaining serum samples were subsequently tested using a conventional quantitative assay.

Results: The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the test were 79.9, 93.0, 65.4, 96.6, and 91.2%, respectively. The sensitivity and specificity of the test changed with variations in the reading time. Quantitative assessment of the intensity of the band was correlated with the PSA value.

Conclusions: PSA testing using this kit can be easily performed. The low cost and speed of the test make it a useful and convenient tool for primary PC screening.

Keywords: Prostate cancer; Prostate-specific antigen; Rapid test; Screening.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Early Detection of Cancer / methods*
  • Hematologic Tests / methods*
  • Humans
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / diagnosis*
  • Time Factors

Substances

  • Prostate-Specific Antigen